MUNICH, December 20, 2010 /PRNewswire/ -- Daiichi Sankyo Europe announced today that Sevikar HCT(R) is now approved in Germany, the first market to launch this new once-daily three-in-one combination product for the treatment of high blood pressure (BP). This new drug combines the three widely prescribed blood pressure treatments - olmesartan medoxomil, amlodipine, and hydrochlorothiazide (HCT) - in one single pill to help effectively control hypertension.(2)

The approval of Sevikar HCT(R) in Germany was granted after the European decentralised procedure was closed with a positive recommendation on the drug.

With the approval of Sevikar HCT(R), Daiichi Sankyo offers physicians a comprehensive range of olmesartan based therapies to help them to successfully treat their patients to the accepted target blood pressure of less than 140/90 mmHg.

*Sevikar HCT(R) is indicated as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide, taken as a dual-component (olmesartan medoxomil and amlodipine or olmesartan medoxomil and hydrochlorothiazide) and a single-component formulation ( hydrochlorothiazide or amlodipine).(3)

"The approval for Sevikar HCT(R) is good news for both patients and physicians in Europe," said Reinhard Bauer, CEO of Daiichi Sankyo Europe, "With olmesartan as the foundation for this new treatment option, we are confident that Sevikar HCT(R) will provide doctors with an additional therapy option to successfully treat their patients to blood pressure targets."

Evidence shows that up to two-thirds of hypertensive patients require multiple medications from different classes of treatment, and many need three or more to reach the accepted blood pressure goal of 140/90 mmHg.(4,5,6) The fixed-dose combination therapy Sevikar HCT(R) will provide doctors with a new treatment option to prescribe to patients, that simplifies treatment, provides patients with a more convenient option and decreases overall pill burden. Giving drugs as a single-pill fixed dose combination significantly improves compliance, and favors BP control compared with the same drugs given separately as two or more pills.(7)

The approval Sevikar HCT(R) completes the Daiichi Sankyo portfolio for the treatment of high blood pressure. The portfolio includes:

- Olmetec(R) (olmesartan medoxomil)

- Olmetec Plus(R) q (olmesartan + hydrochlorothiazide)

- Sevikar(R) q (olmesartan + amlodipine)

- Sevikar HCT(R) (olmesartan + amlodipine + hydrochlorothiazide)